Italian researchers are testing drugs on the basis of bimitrixid as second-line treatment option for echo mesothelioma. Bimitrixid prevents the formation of cellular DNA and RNA which cells need to survive and grow. A study published in the medical journal, "lung cancer", covered the details of the study.
Mesothelioma Cancer rare lung lining and lining of other abdominal cavities. Because it's almost asbestos fibers, once inhaled, can start the process of transition leading to the growth of malignant tumors. Mesothelioma affects fifteen rising to 20,000 people worldwide, and believes that thousands of additional cases are not reported, particularly in developing countries where the use of asbestos and high minimum.
Mesothelioma has a latency period, between 20 and 50 years. When symptoms include coughing, wheezing and markings reflective respiratory infections. And mesothelioma treatments include surgery, chemotherapy and radiotherapy and palliative care. There is no cure for mesothelioma.
The researchers found in the Italian study, specifically drugs bimitrixid mesothelioma patients benefit as second line treatment when the patient has benefited from the same type first-line therapies.
Thirty-one patients who received drugs based on bimitrixid of mesothelioma at least once before where drug management of relapse from 2004 to 2009. All of these patients 3 months or more outside those last treatments. And received fifteen drugs based on bimitrixid alone, while 16 were treated with combination of bimitrixid and drugs based on a current Platinum standard.
Showed forty-eight percent of the patients tested shrunken or tumours that tumors stopped growing. Average monthly 10.5 time survival free of progress and continued also 48% of patients respond well to treatment. Consistent overtime survival for patients receiving free survival time average 12 months after the treatment the same first line type. Patients who have not seen much time survival free 12 months after first-line therapies amounted to 2.5 months just after the second treatment the same font type.
A Japanese study published in International Journal of Clinical Oncology "similar results. Patients who responded to the drug as a treatment based on bimitrixid first line second line therapies have benefited from the same type.
However, the study authors concluded that more research is needed to better decide how to deal with relapse in mesothelioma cases.
This entry was published on Tuesday 18 January 2011 at 8: 14 pm and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.
No comments:
Post a Comment